Page 423 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Dermatologic Aspects of Systemic Vasculitis 397

[60] Radic M, Kaliterna DM, Radic J. Overview of vasculitis and vasculopathy in

rheumatoid arthritis-something to think about. Clin. Rheumatol. 2013; 32:937-942.

[61] Lee JS, Loh TH, Seow SC, et al. Prolonged urticaria with purpura: the spectrum of

clinical and histopathologic features in a prospective series of 22 patients exhibiting the

clinical features of urticarial vasculitis. J. Am. Acad. Dermatol. 2007; 56:994-1005.

[62] Bahrami S, Malone JC, Webb KG, et al. Tissue eosinophilia as an indicator of drug-

induced cutaneous small-vessel vasculitis. Arch. Dermatol. 2006;142:155-161.

[63] Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies.

J. Rheumatol. Suppl. 2010; 85:27-39.

[64] Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis

factor- . Mayo Clin. Proc. 2012; 87:739-745.

[65] Chang A, Osterloh J, Thomas J. Levamisole: a dangerous new cocaine adulterant. Clin.

Pharmacol. Ther. 2010; 88:408-411.

[66] McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and antineutrophil

cytoplasmic antibody-associated disease. Clin. J. Am. Soc. Nephrol. 2011; 6:2799-2805.

[67] Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome

induced by levamisole-contaminated cocaine. Clin. Rheumatol. 2011; 30:1385-1392.

[68] Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to

diagnosis and treatment. Int. J. Dermatol. 2006; 45:3-13.

[69] Ratnam KV, Boon YH, Pang BK. Idiopathic hypersensitivity vasculitis:

clinicopathologic correlation of 61 cases. Int. J. Dermatol. 1995; 34:786-789.

[70] Watts RA, Jolliffe VA, Grattan CE, et al. Cutaneous vasculitis in a defined population-

clinical and epidemiological associations. J. Rheumatol. 1998; 25:920-924.

[71] Hodge SJ, Callen JP, Ekenstam E. Cutaneous leukocytoclastic vasculitis: correlation of

histopathological changes with clinical severity and course. J. Cutan Pathol. 1987;

14:279-284.

[72] Cribier B, Couilliet D, Meyer P, et al. The severity of histopathological changes of

leukocytoclastic vasculitis is not predictive of extracutaneous involvement. Am. J.

Dermatopathol. 1999; 21:532-536.

[73] Barnadas MA, Perez E, Gich I, et al. Diagnostic, prognostic and pathogenic value of the

direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int. J.

Dermatol. 2004; 43:19-26.

[74] Sais G, Vidaller A, Servitje O, Jucgla A, Peyri J. Leukocytoclastic vasculitis and

common variable immunodeficiency: successful treatment with intravenous immune

globulin. J. Allergy Clin. Immunol. 1996; 98:232-223.

Complimentary Contributor Copy